⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9007115 | 0.86 | — | — | |
| SCHEMBL31190199 | 0.80 | — | — | |
| SCHEMBL16467148 | 0.78 | — | — | |
| SCHEMBL10086876 | 0.78 | — | — | |
| SCHEMBL25243391 | 0.77 | ACHE (0.30) | — | |
| SCHEMBL3433873 | 0.72 | BUB1 (0.32) | — | |
| SCHEMBL3433874 | 0.72 | BUB1 (0.32) | — | |
| SCHEMBL11545024 | 0.72 | THRB (0.35) | — | |
| SCHEMBL11341554 | 0.70 | — | — | |
| SCHEMBL4021195 | 0.69 | HPGD (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204320-A1 | PHARMACEUTICALS FOR XEROSIS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-08-12 | — | — | US | disclosed |
| US-7763652-B2 | Prostaglandin derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-07-27 | — | — | US | disclosed |
| US-7737182-B2 | Pharmaceuticals for xerosis | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-06-15 | — | — | US | disclosed |
| US-7718701-B2 | Prostaglandin, e.g., 1R,2R,3R,5R)-5-halo-2-[(1E,3S)-3-cycloalkyl-3-hydroxy-1-propenyl]-3-hydroxycyclopentyl]-(5Z)-5-alkenoic acids; treating in particular, symptoms of atopic dermatitis | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-05-18 | — | — | US | disclosed |
| EP-1211242-B1 | PROSTAGLANDIN DERIVATIVES | TAISHO PHARMACEUTICAL CO LTD (JP) | 2010-01-13 | — | — | EP | disclosed |
| EP-1553083-B1 | PROSTAGLANDIN DERIVATIVES | TAISHO PHARMACEUTICAL CO LTD (JP) | 2009-08-26 | — | — | EP | disclosed |
| US-20060270740-A1 | Prostaglandin derivatives | TAISHO PHARMACEUTICAL CO., LTD. AND FUMIE SATO | 2006-11-30 | — | — | US | disclosed |
| US-20060094788-A1 | Prostaglandin derivatives | FUMIE SATO (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1598335-A1 | PROSTAGLANDIN DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2005-11-23 | — | — | EP | disclosed |
| EP-1553083-A1 | PROSTAGLANDIN DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2005-07-13 | — | — | EP | disclosed |
| EP-0597095-B1 | PROSTAGLANDIN E1 ANALOGUE | TAISHO PHARMACEUTICAL CO LTD (JP) | 1996-10-30 | — | — | EP | disclosed |
| EP-0737676-A1 | PROSTAGLANDIN DERIVATIVE, SALT THEREOF, AND USE THEREOF | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1996-10-16 | — | — | EP | disclosed |
| EP-0501426-B1 | Alpha-methylenecyclopentanone derivative and process for producing the same | NISSAN CHEMICAL IND LTD (JP) | 1996-08-21 | — | — | EP | disclosed |
| US-5491254-A | USEFUL FOR IMPROVING RENAL DISEASES, ISCHEMIC HEART DISEASES OR HEART FAILURE; EXCELLENT PLATELET AGGREGATION INHIBITION ACTIVITY | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1996-02-13 | — | — | US | disclosed |
| US-5449815-A | Prostaglandin E1 analogues | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1995-09-12 | — | — | US | disclosed |
| EP-0666257-A1 | PROSTAGLANDIN E 1? ANALOG | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1995-08-09 | — | — | EP | disclosed |
| EP-0652211-A1 | PROSTAGLANDIN DERIVATIVE | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1995-05-10 | — | — | EP | disclosed |
| US-5380900-A | α-methylenecyclopentanone derivative and process for producing the same | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1995-01-10 | — | — | US | disclosed |
| EP-0597095-A1 | PROSTAGLANDIN E1 ANALOGUE | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1994-05-18 | — | — | EP | disclosed |
| EP-0591532-A1 | PROSTAGLANDIN E 1? ANALOGUE | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1994-04-13 | — | — | EP | disclosed |